Genus, group, species and/or strain specific 16S rDNA Sequences
    63.
    发明公开
    Genus, group, species and/or strain specific 16S rDNA Sequences 审中-公开
    Gattungs-,gruppen-,art-und / oder stammspezifische 16S rDNA-Sequenzen

    公开(公告)号:EP1473370A2

    公开(公告)日:2004-11-03

    申请号:EP04252422.3

    申请日:2004-04-26

    申请人: BioMerieux, Inc.

    IPC分类号: C12Q1/68

    摘要: Materials and methods for identifying unique sites in bacterial 16S and 23S rDNA are provided, as well as specific unique sequences of 16S rDNA in select bacteria. The distinguishing moieties will enable rapid differentiation between families, genera, groups, species, strains, subspecies, and isolates of microorganisms. Such differentiation can be performed by using rapid screening kits in combination with in silico analysis for diagnostic, prognastic, epidemiologic, phylogenetic, and other purposes.

    摘要翻译: 提供了用于识别细菌16S和23S rDNA中独特位点的材料和方法,以及选择性细菌中16S rDNA的特异性独特序列。 区别部分将使家庭,属,群体,物种,菌株,亚种和微生物分离物之间能够快速分化。 这种分化可以通过使用快速筛选试剂盒与用于诊断,预后,流行病学,系统发育和其它目的的计算机分析相结合来进行。

    METHOD OF DETERMINING GLOBAL COAGULABILITY AND HEMOSTATIC POTENTIAL
    64.
    发明公开
    METHOD OF DETERMINING GLOBAL COAGULABILITY AND HEMOSTATIC POTENTIAL 审中-公开
    程序对全球凝血能力和潜力止血

    公开(公告)号:EP1337660A2

    公开(公告)日:2003-08-27

    申请号:EP01983170.0

    申请日:2001-10-18

    申请人: BioMerieux, Inc.

    IPC分类号: C12Q1/56 C12Q1/00

    CPC分类号: G01N33/86

    摘要: A method is disclosed for determining if a patient is hypercoagulable, hypocoagulable or normal. The test involves providing a test sample from the patient and initiating coagulation in the sample in the presence of an activator, which is added to the sample in an amount which will result in intrinsic tenase-dependent fibrin. Then the formation of the intrinsic tenase-dependent fibrin polymerization is monitored over time so as to derive a time-dependent profile, with the results of the fibrin polymerization monitoring determining whether the patient is hypercoagulable, normal or hypocoagulable. The coagulation activator is added in an amount that triggers a thrombin explosion that is dependent on the propagation phase and amplification pathways. In this way, a single assay can assess the hemostatic potential of a sample.